REVIEW ARTICLE

Data Integrity Violations in the Pharmaceutical Industry and Regulatory Measures

M H Ingale[1], M C Tayade[2], Y P Patil[3], Rahul Salunkhe[4]

[1]*Department of Otorhinolaryngology, Dr D. Y. Patil Medical College and Hospital, Dr. D.Y. Patil Vidyapeeth, Pimpri, Pune, India.*
[2]*Department of Physiology, DBVPRMC, Pravara Institute of Medical Sciences (DU) Loni, India.*
[3]*Department of Radiology, Dr D. Y. Patil Medical College and Hospital, Dr. D.Y. Patil Vidyapeeth, Pune, India.*
[4]*Department of Orthopaedics, Dr D. Y. Patil Medical College and Hospital, Dr. D.Y. Patil Vidyapeeth, Pune, India.*

Received: 10th January, 2023; Revised: 13th March, 2023; Accepted: 10th May, 2023; Available Online: 25th June, 2023

ABSTRACT

Data integrity is critical to the pharmaceutical industry, ensuring the reliability, accuracy, and consistency of data generated throughout the product lifecycle. However, data integrity violations have been a growing concern, potentially compromising pharmaceutical products' safety, efficacy, and quality. This systematic review aims to provide an overview of data integrity violations in the pharmaceutical industry and examine the regulatory measures implemented to address this issue. Through a comprehensive analysis of literature, this review highlights the root causes of data integrity violations, the impact on patient safety and public health, and the regulatory landscape governing data integrity in the pharmaceutical industry. It is essential for pharmaceutical companies to prioritize data integrity as an integral part of their operations, from research and development to manufacturing, clinical trials, and post-marketing surveillance. By implementing robust data integrity practices and adhering to regulatory requirements, pharmaceutical companies can protect patient welfare, maintain regulatory compliance, and sustain public trust in the industry.

Keywords: Data integrity, Pharmaceutical industry, Regulatory measures.

International Journal of Pharmaceutical Quality Assurance (2023); DOI: 10.25258/ijpqa.14.2.29

How to cite this article: Ingale MH, Tayade MC, Patil YP, Salunkhe R. Data Integrity Violations in the Pharmaceutical Industry and Regulatory Measures. International Journal of Pharmaceutical Quality Assurance. 2023;14(2):416-420.

Source of support: Nil.

Conflict of interest: None

INTRODUCTION

Data integrity is a fundamental aspect of the pharmaceutical industry, ensuring the reliability, accuracy, and consistency of data generated during pharmaceutical product development, manufacturing, and distribution. It encompasses the completeness, consistency, and validity of data and the measures taken to protect it from unauthorized access, alteration, or loss. Data integrity violations in the pharmaceutical industry have emerged as a significant concern, posing potential risks to patient safety, public health, and the credibility of the industry.[1]

This systematic review aims to comprehensively analyze data integrity violations in the pharmaceutical industry and the regulatory measures implemented to address this critical issue. By examining relevant literature and case studies, this review seeks to identify the root causes of data integrity violations, understand their impact on patient safety and public health, and evaluate the effectiveness of regulatory frameworks in ensuring data integrity.

METHODOLOGY

Search Strategy

The search strategy for this systematic review involved a comprehensive search of relevant literature from various databases, including PubMed, Scopus, Web of Science, and Embase. The search was conducted using a combination of keywords related to data integrity violations, the pharmaceutical industry, and regulatory measures. The search terms included, data integrity, data integrity violations, pharmaceutical industry, pharmaceutical manufacturing, good manufacturing practice (GMP), good clinical practice (GCP), good laboratory practice (GLP), Regulatory guidelines, Regulatory authorities, compliance etc.

These keywords were combined using Boolean operators (AND, OR) to refine the search results and ensure the inclusion of relevant studies. In addition to database searches, hand-searching of reference lists of identified articles and relevant

**Author for Correspondence: drmctayade@gmail.com*

journals was also conducted to identify additional studies that might have been missed in the initial search.

The search strategy aimed to include studies published in English and covered a period up to the present date. The search was not limited to a specific geographical region to capture a wide range of perspectives on data integrity violations in the pharmaceutical industry and the regulatory measures implemented globally.

The inclusion and exclusion criteria were applied during the screening process to select relevant articles based on their titles, abstracts, and full texts. The selected studies were then analyzed and synthesized to provide a comprehensive review of data integrity violations in the pharmaceutical industry and the regulatory measures in place to address them.

STUDY SELECTION CRITERIA

The study selection criteria for this systematic review were defined to ensure the inclusion of relevant, high-quality studies that address the research objectives. The following criteria were applied during the screening process:

1. Relevance to the topic
2. Publication Type: Only peer-reviewed journal articles and conference proceedings were considered for inclusion. Dissertations, theses, books, and non-peer-reviewed sources were excluded.
3. Language: Studies published in English were included to facilitate analysis and understanding.
4. Timeframe: Studies published up to the present date were considered, allowing for an understanding of recent developments in the field.
5. Study Design: Both quantitative and qualitative studies were included.
6. Study Participants: Studies involving participants from the pharmaceutical industry, regulatory authorities, healthcare professionals, and relevant stakeholders were considered.
7. Exclusion Criteria: Studies that did not directly address data integrity violations in the pharmaceutical industry or did not provide information on regulatory measures were excluded. Additionally, studies that were not accessible or did not provide sufficient data were excluded.

The screening process involved three stages: title screening, abstract screening, and full-text screening.

The screening process was conducted independently by two reviewers, and any discrepancies or uncertainties were resolved through discussion and consensus. The PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) guidelines were followed to ensure transparency and rigor throughout the study selection process.

Data Extraction and Analysis

A standardized data extraction form was created to capture relevant information from each selected study. The form included fields such as study characteristics (author, year, title), study design, sample size, data integrity violations identified, regulatory measures discussed, key findings, and any other relevant information.

Thematic analysis was conducted to identify key themes and subthemes emerging from the data. This involved coding the extracted information and grouping similar concepts together. Themes were derived from the data and represented the main findings and patterns identified in the studies.

Data Integrity Violations in the Pharmaceutical Industry

1. **Falsification and Manipulation of Data:** Falsification and manipulation of data represent significant data integrity violations in the pharmaceutical industry. These practices involve deliberately altering, fabricating, or omitting data to present inaccurate or misleading information. This section discusses the various forms of falsification and manipulation of data observed in the pharmaceutical industry, their potential consequences, and the regulatory measures in place to prevent and detect such violations.[2,3,4]

Forms of Falsification and Manipulation of Data[5]

1. Fabrication of Data: Fabrication involves creating data that were never generated or conducting experiments and trials with predetermined outcomes. This practice can involve inventing patient data, laboratory results, or efficacy and safety outcomes of pharmaceutical products.
2. Selective Reporting: Selective reporting refers to the intentional omission of unfavorable data or results, while emphasizing positive or desired outcomes. This practice can skew the interpretation of study findings and mislead regulators, healthcare professionals, and patients.
3. Data Alteration: Data alteration involves changing or manipulating existing data to fit a desired outcome. This can include modifying numerical values, adjusting statistical analyses, or altering images or graphs.

Consequences of Falsification and Manipulation of Data[3-6]

Falsification and manipulation of data in the pharmaceutical industry can have serious consequences for patient safety, public health, and scientific integrity. Some of the potential consequences include:

1. Compromised Efficacy and Safety: Falsified or manipulated data can misrepresent pharmaceutical products' true efficacy and safety profile. This can lead to the approval and marketing of ineffective products or carrying unknown risks, jeopardizing patient health and safety.
2. Inaccurate Risk-Benefit Assessments: Falsification of data can result in inaccurate assessments of the risks and benefits associated with pharmaceutical products. This can lead to incorrect decisions regarding drug approvals, labeling, and patient treatment options.
3. Ethical Concerns: Falsification and manipulation of data violate ethical principles, including integrity, honesty, and transparency in scientific research and the pharmaceutical industry. It undermines trust and credibility in the industry and jeopardizes the rights and welfare of patients.

Unauthorized Access and Changes[7]

Unauthorized access and changes to data represent another important data integrity violation in the pharmaceutical

industry. This involves the unauthorized entry or alteration of data by individuals who do not have the proper authorization or permissions. Unauthorized access and changes can compromise data accuracy, reliability, and confidentiality, leading to serious consequences. In this section, we will explore the different aspects of unauthorized access and changes, their potential impact, and the regulatory measures in place to prevent and detect such violations.

Unauthorized Access[8]

Unauthorized access refers to the unauthorized entry or viewing of data by individuals who do not have the necessary permissions or authority. This can occur through various means, such as hacking into computer systems, unauthorized use of login credentials, or physical access to restricted areas or documents.

Unauthorized Changes[9,10]

Unauthorized changes involve altering, deleting, or adding data without proper authorization. This can include modifying test results, changing manufacturing records, or tampering with clinical trial data. Unauthorized changes can be intentional or accidental, but both can have serious implications for data integrity.

Impact of Unauthorized Access and Changes[11]

Unauthorized access and changes to data can have significant consequences for the pharmaceutical industry, including:

1. Data Integrity Compromise: Unauthorized access and changes can compromise the integrity of data, leading to inaccurate or unreliable information. This can have implications for decision-making processes, regulatory submissions, and patient safety.
2. Intellectual Property Theft: Unauthorized access to confidential or proprietary data can result in intellectual property theft. This can include the theft of research and development data, trade secrets, or proprietary formulations, undermining the competitive advantage of pharmaceutical companies.
3. Regulatory Compliance Issues: Unauthorized access and changes to data can lead to non-compliance with regulatory requirements. Regulatory authorities expect pharmaceutical companies to maintain secure systems and controls to prevent unauthorized access and changes, and violations can result in penalties, regulatory actions, or loss of reputation.[12]

Inadequate Data Documentation and Retention[13]

Inadequate data documentation and retention is a critical data integrity violation in the pharmaceutical industry. It refers to the failure to appropriately record, organize, and retain data generated during various stages of pharmaceutical development, manufacturing, and distribution. Insufficient documentation and retention practices can lead to data inaccuracies, incomplete information, and difficulties in verifying and reproducing results. In this section, we will explore the implications of inadequate data documentation and retention and the regulatory measures in place to address this issue.

Implications of Inadequate Data Documentation and Retention[14]

1. Data Integrity and Reliability: Inadequate documentation and retention practices can compromise the integrity and reliability of data. Without proper documentation, it becomes challenging to trace the origin of data, assess its accuracy, and ensure its consistency. This can undermine the credibility of research findings, manufacturing processes, and regulatory submissions.
2. Reproducibility and Verification: Inadequate data documentation and retention hinder reproducing and verifying research findings and manufacturing processes. Without complete and organized data, it becomes difficult for independent parties, including regulatory authorities and scientific peers, to assess the validity and reliability of results.
3. Compliance with Regulatory Requirements: Regulatory authorities expect pharmaceutical companies to maintain comprehensive and well-organized data documentation. Inadequate practices can result in non-compliance with regulatory requirements, potentially leading to regulatory actions, delays in product approvals, and loss of market reputation.
4. Quality Control and Risk Assessment: Inadequate data documentation and retention practices can impede effective quality control and risk assessment processes. Complete and accurate data documentation is essential for identifying trends, analyzing deviations, and making informed decisions regarding product quality and safety.[15,16]

Regulatory Measures to Address Inadequate Data Documentation and Retention

Regulatory authorities and industry organizations have implemented several measures to address inadequate data documentation and retention. These measures include:[17,18,19]

Good Documentation Practices (GDP)

GDP guidelines provide recommendations for the documentation of data, ensuring completeness, accuracy, and traceability. These guidelines outline best practices for recording observations, procedures, and results in a clear, organized, and timely manner.

Data Management Systems

Pharmaceutical companies are encouraged to implement robust data management systems that facilitate proper documentation, storage, and retention of data. These systems should include appropriate controls to ensure data integrity, security, and accessibility.

Standard Operating Procedures (SOPs)

SOPs should be established and followed to guide employees on data documentation and retention practices. SOPs provide clear instructions on recording, storing, retrieving, and retaining

data, ensuring consistency and compliance with regulatory requirements.

Record Retention Periods

Regulatory authorities specify record retention periods for different types of data generated in the pharmaceutical industry. These retention periods ensure that data are retained for a sufficient duration to allow verification, inspection, and review by regulatory authorities and other stakeholders.

Regulatory Inspections and Audits

Regulatory authorities conduct inspections and audits to assess the compliance of pharmaceutical companies with data documentation and retention requirements. These inspections help identify deficiencies and non-compliance and may result in corrective actions or penalties.

Training and Education

Training programs should be provided to employees to enhance their understanding of the importance of data documentation and retention. Employees should be educated on the regulatory requirements, best practices, and the consequences of inadequate data documentation.

Poor Data Backup and Recovery

Poor data backup and recovery practices represent a significant data integrity violation in the pharmaceutical industry. It refers to the inadequate or insufficient measures taken to back up and protect critical data and the inability to recover data in the event of data loss or system failures. Poor data backup and recovery practices can result in permanent data loss, hinder business continuity, and compromise the integrity and availability of essential information. In this section, we will discuss the implications of poor data backup and recovery and the regulatory measures and best practices to mitigate these risks.

Lack of Oversight and Monitoring[20]

Lack of oversight and monitoring is a critical data integrity violation in the pharmaceutical industry. It refers to the absence or inadequate implementation of measures to supervise, evaluate, and ensure the integrity of data-related activities. Insufficient oversight and monitoring can result in data inaccuracies, unauthorized access, data manipulation, and other data integrity breaches. In this section, we will discuss the implications of lack of oversight and monitoring and the regulatory measures and best practices to address this issue.

Regulatory Measures for Ensuring Data Integrity[3,4,7]

Regulatory authorities have implemented various measures to ensure data integrity in the pharmaceutical industry. These measures aim to establish standards, guidelines, and requirements that pharmaceutical companies must follow to maintain their data's integrity, reliability, and traceability. Some of the key regulatory measures for ensuring data integrity include:

Good Manufacturing Practice (GMP)

GMP guidelines provide a framework for ensuring the quality and integrity of pharmaceutical manufacturing processes. They include requirements for data integrity, documentation practices, recordkeeping, and data management throughout the manufacturing lifecycle.

Good Laboratory Practice (GLP)

GLP guidelines establish principles for the conduct of non-clinical laboratory studies. These guidelines emphasize the importance of data integrity, including accurate and complete recording of study data, adherence to standard operating procedures, and documentation of deviations or changes.

Good Clinical Practice (GCP)

GCP guidelines provide standards for the design, conduct, monitoring, and reporting of clinical trials. They emphasize the need for data integrity and reliable documentation, including accurate recording of trial data, adherence to protocols, and maintenance of source documentation.

21 CFR Part 11

In the United States, 21 CFR Part 11 outlines the requirements for electronic records and electronic signatures in the pharmaceutical industry. It provides guidance on ensuring electronic records' authenticity, integrity, and reliability, including electronic data capture systems and electronic signatures.

Annex 11 (EU)

Annex 11 of the European Union's Good Manufacturing Practice guidelines focuses on computerized systems used in pharmaceutical manufacturing. It provides requirements for data integrity, electronic records, electronic signatures, and the validation of computerized systems.

Data Audit Trails and Controls

Regulatory authorities expect pharmaceutical companies to implement robust data audit trails and controls within their electronic systems. These systems should record and track all activities and changes made to data, ensuring a clear audit trail that can be reviewed for data integrity purposes.

Regulatory Inspections and Audits

Regulatory authorities conduct inspections and audits of pharmaceutical companies to assess their compliance with data integrity regulations. These inspections involve reviewing data management systems, and documentation practices, and verifying data accuracy and authenticity.

Training and Education

Regulatory authorities and industry organizations emphasize the importance of training and education programs on data integrity. These programs aim to raise awareness and understanding of data integrity requirements and promote the development of skills necessary for maintaining data integrity throughout the pharmaceutical industry.

Risk-based Approaches

Regulatory authorities encourage the implementation of risk-based approaches to data integrity, where companies identify and assess potential risks to data integrity and implement appropriate controls and measures to mitigate those risks.

CONCLUSION

In conclusion, data integrity violations pose significant risks to the pharmaceutical industry and can have far-reaching consequences for patient safety, regulatory compliance, and public trust. This systemic review has explored various data integrity violations in the pharmaceutical industry, including falsification and manipulation of data, unauthorized access and changes, inadequate data documentation and retention, poor data backup and recovery practices, and lack of oversight and monitoring.[18,19]

It is essential for pharmaceutical companies to prioritize data integrity as an integral part of their operations, from research and development to manufacturing, clinical trials, and post-marketing surveillance. By implementing robust data integrity practices and adhering to regulatory requirements, pharmaceutical companies can protect patient welfare, maintain regulatory compliance, and sustain public trust in the industry.

REFERENCES

5. World Health Organization. (2016). Guidance on Good Data and Record Management Practices.
6. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH). ICH Harmonised Tripartite Guideline: Good Manufacturing Practice Guide for Active Pharmaceutical Ingredients.
7. Borchers AT, Hagie F, Keen CL, Gershwin ME. The history and contemporary challenges of the US Food and Drug Administration. Clin Ther. 2007 Jan;29(1):1-16.
8. Charoo NA, Khan MA, Rahman Z. Data integrity issues in pharmaceutical industry: Common observations, challenges and mitigations strategies. Int J Pharm. 2023 Jan 25;631:122503
9. Rattan AK. Data Integrity: History, Issues, and Remediation of Issues. PDA J Pharm Sci Technol. 2018 Mar-Apr;72(2):105-116.
10. De la Torre BG, Albericio F. The Pharmaceutical Industry in 2019. An Analysis of FDA Drug Approvals from the Perspective of Molecules. Molecules. 2020 Feb 9;25(3):745.
11. D H Nandal , S N Mahajan , S P Narwane , R R Kunkulol , T Baheti , Study of ADR (Adverse Drug Reactions) Reporting in Pravara Rural Hospital, Loni , Pravara Medical Review, 2019;11(1), 1-7
12. De la Torre G.B., Albericio F. The Pharmaceutical Industry in 2018. An Analysis of FDA Drug Approvals from the Perspective of Molecules. Molecules. 2019;24:809
13. Jarvis L.M. The new drugs of 2018. Chem. Eng. News. 2019;97:33–37.
14. Dr.Vandana S Pulate , Dr. Sanjay S Varade , Dr Priyanka B Gulve , Dr.Rahul R Kunkulol, Effect of add on L-arginine on Mean arterial pressure in hypertensive patients on antihypertensive treatment , Pravara Medical Review; March 2023, 15 (01), 5 – 10
15. Beck A., Goetsch L., Dumontet C., Corvaïa N. Strategies and challenges for the next generation of antibody–drug conjugates. Nat. Rev. Drug Discov. 2017;16:315–337.
16. Xu Z, Eichler B, Klausner EA, Duffy-Matzner J, Zheng W. Lead/Drug Discovery from Natural Resources. Molecules. 2022 Nov 28;27(23):8280
17. Otsuki K., Li W., Miura K., Asada Y., Huang L., Chen C.-H., Lee K.-H., Koike K. Isolation, structural elucidation, and anti-HIV activity of daphnane diterpenoids from Daphne odora. J. Nat. Prod. 2020;83:3270–3277.
18. Jayaraj, Y.M., Tayade, M.C., Ethical Dilemma in Medical Professionals in COVID-19 Pandemics and Pravara Initiatives , Pravara Medical Review, 2020, 12(4), 2–7
19. Kaur R., Rani P., Atanasov A.G., Alzaharani Q., Gupta R., Kapoor B., Gulati M., Chawla P. Discovery and development of antibacterial agents: Fortuitous and designed. Mini-Rev. Med. Chem. 2022;22:984–1029.
20. Dhokikar Gajanan Digambarrao, Padmanabhan P , Baheti Tushar Chandrakant , Study of Quality Indicators (QIs) of Clinical Biochemistry Laboratory in rural hospital, Loni , Pravara Medical Review ; March 2021, 13(01) , 18 - 23
21. Khare P., Sahu U., Pandey S.C., Samant M. Current approaches for target-specific drug discovery using natural compounds against SARS-CoV-2 infection. Virus Res. 2020;290:198169
22. Treml J., Gazdova M., Smejkal K., Sudomova M., Kubatka P., Hassan S.T.S. Natural products-derived chemicals: Breaking barriers to novel anti-HSV drug development. Viruses. 2020;12:154.
23. Dheman N., Mahoney N., Cox E.M., Farley J.J., Amini T., Lanthier M.L. An analysis of antibacterial drug development trends in the United States, 1980–2019. Clin. Infect. Dis. 2021;73:e4444–e4450.
24. Outterson K. A shot in the arm for new antibiotics. Nat. Biotechnol. 2019;37:1110–1112.